Businesses which rely on patents to protect their valuable innovations, or want to navigate intellectual property rights to access new markets, will have to fundamentally change how they approach patent enforcement and defensive strategies in Europe when the Unitary Patent and Unified Patent Court (UPC) go live in 2023.
The new court structure represents the biggest overhaul of the European patent system in history, and will present transformational opportunities for businesses.
Our experts investigate the implications of this game-changing new system.
Rechtsanwalt, Partner, Head of German Life Sciences
Marc is Deputy Head of Pinsent Masons Germany. He also heads the German Life Sciences team. He specialises in supporting pharmaceutical, medical device and other high-tech companies in navigating through the complex world of contentious and non-contentious intellectual property.
Partner
Christopher is based in London and Dublin and is an IP litigation specialist. He graduated in Chemistry and spent time as a research chemist. His principal area of expertise is pharmaceutical patent litigation for both innovator and generic/biosimilar clients. Christopher has significant experience of leading multi-jurisdictional teams and managing and coordinating patent litigation.
Partner
Karen is a contentious intellectual property and life sciences specialist. She provides strategic advice to clients across all sectors in complex patent disputes and other intellectual property litigation. She also advises life sciences clients on IP rights and regulatory matters.
Partner, Co-Head of Intellectual Property
Judith is a life sciences specialist having over 20 years of experience in complex multijurisdictional patent litigation as well as extensive experience in pharma regulatory matters and transactional life sciences.